Comment: Valproate dose effects differ across congenital malformations

Neurology

Volumn 81, Issue 11, 2013, Pages 1002-

  Meador, Kimford J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID;

CONGENITAL MALFORMATION; DOSE RESPONSE; FETUS MALFORMATION; HUMAN; HYPOSPADIAS; NOTE; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; SPINAL DYSRAPHISM;

ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; NERVOUS SYSTEM MALFORMATIONS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; VALPROIC ACID;

EID: 84884544038     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a43eb7     Document Type: Note

References (4)

1. Harden CL, Meador KJ, Hauser WA, et al. Update of practice parameter: management issues for women with epilepsy: focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics & Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73:133-141.
2. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185-2193.
3. Werler MM, Ahrens KA, Bosco JL, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 2011;21:842-850.
4. Vajda FJ, O'Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal malformations associated with valproate. Neurology 2013;81:999-1003.